https://www.selleckchem.com/pr....oducts/larotrectinib
6% female; mean age, 46.3years; 52.9% with diabetic gastroparesis) were included. Treatment with velusetrag 30mg significantly increased the proportion of subjects with ≥20% reduction from baseline GE t compared with placebo (52% vs 5%, P=0.002), and GE t was numerically reduced following all three doses of velusetrag relative to placebo treatment. Efficacy was similar between subjects with diabetic and idiopathic gastroparesis. Velusetrag treatment was generally well tolerated; most TEAEs were mild and related to GI transit accel